Our Content Hub

AVIM Therapy Breakthrough Device Designation Shareholder Implications

Apr 22, 2025, 2:30:00 AM / by Orchestra BioMed posted in Regulatory

0 Comments

OBIO | AVIM Therapy Breakthrough Device Designation Shareholder Implications

This week marks a major milestone for Orchestra BioMed that has potentially significant implications for the commercial potential of AVIM therapy that OBIO is pursuing with its strategic partner, Medtronic.

Read More